This podcast, recorded at the MAPS 2022 Global Annual Meeting, addresses the unique position of Medical Affairs in the rare disease space & how our work in this area is essential for patient benefit.
Medical technologies such as medical devices and diagnostics are set apart from pharmaceuticals in that successful deployment depends on not only equipping health care providers with the theoretical knowledge of best and safest use but also ensuring users’ practical competence. Simply, with medical technologies across the spectrum from noninvasive diagnostics to high-risk therapeutics, clinical outcomes and patient safety depend on both proper education and proper training. In fact, this training is often a gatekeeper for use, as governments, trade organizations, and even hospitals may require medical staff to be adequately trained before new medical devices can be used in their settings. External education and training of health care professionals is largely the responsibility of External Education teams within Medical Affairs. This article details the importance of the External Education function and describes best practices for the implementation of External Education related to medical diagnostics/devices within a manufacturer’s organization.
Medical Affairs describes itself as a third strategic pillar in the biopharmaceutical and MedTech industries alongside R&D and Commercial. But is this truly the case or is Medical Affairs' strategic role still aspirational? And if it is in some ways aspirational, what does Medical Affairs need to do in order to truly achieve its position alongside R&D and Commercial? Here, three Medical Affairs leaders discuss these questions and offer their perspective for the future of the function.
In this white paper, MedComms, Field Medical and Insights Focus Area Working Groups (FAWGs) demonstrate the value of and elucidate best practices for an insights-driven collaborative approach to creating an iMC S/P.
MAPS is honored to announce the appointment of William (Bill) Sigmund, MD, MHS, EVP and Chief Medical Officer at Becton Dickinson, to the MAPS Board of Directors.
This white paper provides Medical Affairs professionals with the background and history of Real-World Evidence, and its applications in the biopharma industry to benefit patients.
How do leaders make their way to Medical Safety & Pharmacovigilance? The routes are diverse but one constant remains true: They are extremely committed to being an independent voice that amplifies their organization’s commitment to Patient Centricity.
Digitalization offers Medical Affairs teams the opportunity to rethink strategy and actions across the lifecycle of traditional and nontraditional products.
This podcast previews the MAPS 2022 Global Annual Meeting session “How Medical Affairs can best support internal and external collaborations in patient engagement,” that details the unique role of Medical Affairs in patient engagement.
One of the pandemic’s silver linings may well be gains in participation levels and the volume and quality of insights generated by eliminating the constraints of face-to-face interaction.